Mast Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1995-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://masttherapeutics.com
Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2007-11-19
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 1200
- Registration Number
- NCT00337389
- Locations
- 🇺🇸
Research Site In, San Diego, California, United States
Research Center In, Zrenjanin, Former Serbia and Montenegro
🇺🇸Mercy General Hospital, Sacramento, California, United States
Clinical Trial in Patients With Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2008-08-25
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT00235898
- Locations
- 🇮🇳
Department of Oncology, Christian Medical College, Vellore, Tamil Nadu, India
🇮🇳Global Hospital, Hyderabad, Andhra Pradesh, India
🇷🇸Clinic for Internal Medicine, Institute for Oncology Sremska, Sremska Kamenica, Serbia
Clinical Trial in Patients With Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-10-14
- Last Posted Date
- 2007-11-27
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00081627
- Locations
- 🇺🇸
Mercy General Hospital, Sacramento, California, United States
🇺🇸Killeen Cancer Center, Killeen, Texas, United States
Institute of Oncology, Sremska Kamenica, Former Serbia and Montenegro
Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease
Phase 3
Completed
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2012-03-06
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT00004408
© Copyright 2024. All Rights Reserved by MedPath